These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25806200)

  • 1. Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials.
    Petrelli F; Barni S
    Transl Lung Cancer Res; 2013 Feb; 2(1):6-13. PubMed ID: 25806200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer.
    Petrelli F; Barni S
    Ann Oncol; 2013 Jan; 24(1):186-92. PubMed ID: 22898038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer.
    Shimokawa M; Kogawa T; Shimada T; Saito T; Kumagai H; Ohki M; Kaku T
    J Cancer; 2018; 9(5):872-879. PubMed ID: 29581765
    [No Abstract]   [Full Text] [Related]  

  • 4. A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration.
    He Q; Li Q; Lv F; Kaitin KI; Shao L
    Ther Innov Regul Sci; 2021 Jul; 55(4):676-684. PubMed ID: 33683659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.
    Hayashi H; Okamoto I; Taguri M; Morita S; Nakagawa K
    Clin Lung Cancer; 2013 May; 14(3):261-6. PubMed ID: 23107465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
    Petrelli F; Barni S
    Med Oncol; 2014 Jan; 31(1):776. PubMed ID: 24271313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
    Tang PA; Bentzen SM; Chen EX; Siu LL
    J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer.
    Kawakami H; Okamoto I; Hayashi H; Taguri M; Morita S; Nakagawa K
    Eur J Cancer; 2013 Sep; 49(14):3003-9. PubMed ID: 23791540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis.
    Ghali F; Zhao Y; Patel D; Jewell T; Yu EY; Grivas P; Montgomery RB; Gore JL; Etzioni RB; Wright JL
    Eur Urol Open Sci; 2023 Jan; 47():58-64. PubMed ID: 36601043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
    Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
    Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer.
    Imai H; Yamaguchi O; Mori K; Hashimoto K; Akagami T; Shinomiya S; Miura Y; Shiono A; Mouri A; Kaira K; Kobayashi K; Kagamu H
    Thorac Cancer; 2021 Apr; 12(8):1171-1179. PubMed ID: 33626218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of post-progression survival in lung cancer.
    Imai H; Kaira K; Minato K
    Thorac Cancer; 2017 Sep; 8(5):379-386. PubMed ID: 28627767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
    Hua T; Gao Y; Zhang R; Wei Y; Chen F
    BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Barni S
    Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):124-31. PubMed ID: 25865683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis.
    Sjoquist KM; Lord SJ; Friedlander ML; John Simes R; Marschner IC; Lee CK
    Ther Adv Med Oncol; 2018; 10():1758835918788500. PubMed ID: 30093922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer.
    Hayashi H; Okamoto I; Morita S; Taguri M; Nakagawa K
    Ann Oncol; 2012 Jun; 23(6):1537-41. PubMed ID: 22039091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
    Kotake M; Miura Y; Imai H; Mori K; Sakurai R; Kaira K; Tomizawa Y; Minato K; Saito R; Hisada T
    Chemotherapy; 2017; 62(4):205-213. PubMed ID: 28380484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
    Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
    Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure.
    Suzuki H; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Kawase I
    Asia Pac J Clin Oncol; 2015 Jun; 11(2):121-8. PubMed ID: 24811212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer.
    Beauchemin C; Cooper D; Lapierre MÈ; Yelle L; Lachaine J
    Onco Targets Ther; 2014; 7():1101-10. PubMed ID: 24971020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.